FDA 483 - Chromatography Institute of America, Inc. - August 29, 2025

During an inspection conducted from July 17 to August 29, 2023, the FDA identified significant quality system deficiencies at Medtronic Navigation Inc.'s Louisville, CO facility. The inspection revealed four key observations related to the company's compliance with medical device regulations.

Firstly, the firm's procedures for corrective and preventive actions (CAPA) were found to be inadequate, particularly in verifying the effectiveness of implemented solutions. A specific CAPA related to StealthStation S8 system crashes was closed despite recurring issues, indicating a failure to ensure the action truly prevented future occurrences. This was a repeat observation from a 2009 inspection.

Secondly, Medtronic Navigation Inc. failed to adequately review, evaluate, and investigate complaints. Over 260 complaints concerning StealthStation S8 system crashes, freezes, or reboots during patient surgery between January 2022 and July 2023 were closed without determining a root cause for the malfunctions.

Thirdly, the procedures for receiving and evaluating complaints lacked clear guidance on when an investigation is necessary for product malfunctions. This deficiency directly contributed to the inadequate investigations noted in the second observation and was also a repeat finding from 2009.

Finally, the company's CAPA procedures did not ensure that information about quality problems or nonconforming products was properly shared with personnel responsible for product quality or problem prevention. A previous audit had identified the need to update complaint handling procedures, but this issue persisted.

Medtronic Navigation Inc. is required to address these systemic issues, revise and implement robust CAPA and complaint handling procedures, ensure thorough root cause investigations, and verify the effectiveness of all corrective actions to comply with medical device quality system regulations.